<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902353</url>
  </required_header>
  <id_info>
    <org_study_id>K180501J</org_study_id>
    <nct_id>NCT03902353</nct_id>
  </id_info>
  <brief_title>Screening of Pulmonary Veino Occlusive Disease in Heterozygous EIF2AK4 Mutation Carriers</brief_title>
  <acronym>DELPHI-4</acronym>
  <official_title>Screening of Pulmonary Veino Occlusive Disease in Heterozygous EIF2AK4 Mutation Carriers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary Veino Occlusive Disease (PVOD) is a rare form of pulmonary arterial hypertension,
      characterised by a poor prognosis. Recent studies demonstrated that heritable form of
      pulmonary veino occlusive diseaseis due to bi-allelic mutations in EIF2AK4 gene. heritable
      pulmonary veino occlusive disease is an autosomal recessive disease. In the french referal
      center of severe PH, ulmonary veino occlusive disease patients carriers of bi-allelic
      mutations in EIF2AK4 gene were identified. Genetic counselling in these families allowed to
      identified herozygous carriers of a single mutation in EIF2AK4 gene. However, to date,
      nothing is known about the risk of these persons of developping pulmonary diseases. It
      appears essential to determine the clinical, functional, echocardiographic and radiologics
      characteristics of these persons, and their risk of developping Pulmonary veino occlusive
      disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the investigators will evaluate the subjects at inclusion after informed by a clinical
      evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of
      right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an
      electrocardiogram, an echocardiography , an abdomina ulstrasound, a Cardiopulmonary exercise
      testing, a lung function tests , arterial blood gases.

      At one and two years, a phone call will be made to to participants evaluate dyspnea and
      intercurrent events in all subjects. In the presence of pulmonary veino occlusive diseaseis
      symptoms, a new evaluation will be proposed in order to confirm of not pulmonary veino
      occlusive diseaseis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of characteristics of asymptomatic heterozyous EIF2AK4 mutation carriers and monitor these subjects' clinical, functional, biological, echocardiographic</measure>
    <time_frame>1 year</time_frame>
    <description>frequency of abnormalities observed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>predictive factors of the occurrence of PVOD follow prospectively a cohort of asymptomatic heterozyous EIF2AK4 mutation carriers to determine predictive factors of the occurrence of VOD</measure>
    <time_frame>1 year</time_frame>
    <description>number of heterozygous EIF2AK4 mutation carriers who will develop Pulmonary Veno-Occlusive Disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mutation</condition>
  <condition>Genetic Syndrome</condition>
  <arm_group>
    <arm_group_label>Adults without diagnosis of PH</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adults without diagnosis of PH carrying an heterozygous EIF2AK4</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.</intervention_name>
    <description>will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.</description>
    <arm_group_label>Adults without diagnosis of PH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adult (age ≥18 years of age at the date of inclusion),

          -  With an identification of the presence of a mutation of the EIF2AK4 gene in the
             heterozygous state,

          -  Having given free and informed consent.

        Exclusion Criteria:

          -  Minor (age &lt;18 years),

          -  Patient with known Pulmonary veino occlusive disease or Pulmonary arterial
             hypertension

          -  Woman having started a pregnancy or breastfeeding

          -  protected adult persons,

          -  Persons deprived of their liberty,

          -  People in emergency,

          -  Those who refused or were unable to give informed consent,

          -  Contraindication to the exercise test (acute coronary syndrome, syncope, tight
             stenotic valve disease ...) See the list of relative and absolute contraindications to
             the exercise test (chapter 6.2).

          -  No affiliation to a social security scheme (beneficiary or beneficiary).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MONTANI David, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MONTANI David, PhD</last_name>
    <phone>01.45.21.79.76</phone>
    <email>david.montani@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GIRERD Barbara, MPCG, PhD</last_name>
    <phone>01 45 21 79 72</phone>
    <email>barbara.girerd@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>David MONTANI</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>Krémlin Bicêtre</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David MONTANI, MD</last_name>
      <phone>01.45.21.79.76</phone>
      <email>david.montani@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marc HUMBERT, PhD</last_name>
      <phone>01.45.21.79.76</phone>
      <email>marc.humbert@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>January 17, 2020</last_update_submitted>
  <last_update_submitted_qc>January 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary veino occlusive disease, pulmonary hypertension</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

